SCHEMBL1706265

SCHEMBL1706265

CC(N)(C(N)=O)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.65
KMT2A Q03164 1/20 0.65
CYP1A2 P05177 3/20 0.48
CYP2D6 P10635 1/20 0.48
KCNN4 O15554 8/20 0.47
CYP2C19 P33261 2/20 0.47
HIF1A Q16665 1/20 0.47
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
HTT P42858 1/20 0.44
TAAR1 Q96RJ0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1706266 1.00 MAPT (0.65) MAPTKMT2ACYP1A2CYP2D6KCNN4
SCHEMBL1706268 1.00 MAPT (0.65) MAPTKMT2ACYP1A2CYP2D6KCNN4
Hydrochloric Acid SCHEMBL16776633 0.98 MAPT (0.63) MAPTKMT2ACYP1A2CYP2D6KCNN4
SCHEMBL29758021 0.88 MAPT (0.57) MAPTKMT2AKCNN4
SCHEMBL59841 0.84 CYP1A2 (0.58) MAPTKMT2ACYP1A2CYP2D6KCNN4
SCHEMBL5181868 0.84 MAPT (0.56) MAPTKMT2ACYP1A2CYP2D6KCNN4
SCHEMBL222049 0.84 CYP1A2 (0.58) MAPTKMT2ACYP1A2CYP2D6KCNN4
SCHEMBL220775 0.84 CYP1A2 (0.58) MAPTKMT2ACYP1A2CYP2D6KCNN4
Hydrochloric Acid SCHEMBL304449 0.82 CYP1A2 (0.56) MAPTKMT2ACYP1A2CYP2D6KCNN4
Hydrochloric Acid SCHEMBL1455022 0.82 CYP1A2 (0.56) MAPTKMT2ACYP1A2CYP2D6KCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP claimed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO claimed
EP-1426356-B1 INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF MIRTAZAPINE AND THE PRODUCTION METHODS THEREOF MEDICHEM SA (ES) 2008-04-16 EP claimed
US-7265223-B2 Intermediate compounds for the preparation of mirtazapine and production methods thereof MEDICHEM, S.A. (ES) 2007-09-04 US claimed
US-20040236107-A1 Intermediate compounds for the preparation of mirtazapine and the production methods thereof MEDICHEM, S.A. (ES) 2004-11-25 US claimed
EP-1426356-A1 INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF MIRTAZAPINE AND THE PRODUCTION METHODS THEREOF Medichem S.A. (ES) 2004-06-09 EP claimed
CN-86105641-A The method for preparing antianaphylaxis and antibronchospasm of N-dibenzyl-diazacyclo alkyl-alkyl-anilide 1987-04-01 CN claimed
CN-114787135-A Substituted imidazole carboxamides and their use in the treatment of medical disorders 比亚尔R&D投资股份公司 2022-07-22 CN disclosed
EP-3917627-A1 ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Ideaya Biosciences, Inc. (US) 2021-12-08 EP disclosed
WO-2020160134-A1 ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-08-06 WO disclosed
CN-105813653-B Methylene carbamate linkers for use with target-drug conjugates 西雅图基因公司 2020-06-26 CN disclosed
CN-105732414-B The method of control of amide derivatives, the noxious organism control agent containing the amide derivatives and harmful organism 三井化学AGRO株式会社 2019-05-03 CN disclosed
CN-109689111-A Pyrrolobenzodiazepines * prodrug and its antibody conjugates 基因泰克公司 2019-04-26 CN disclosed
EP-0915858-A1 INTERMEDIATES FOR THE PREPARATION OF 2-IMIDAZOLINE-5-ONES Rhone Poulenc Agro (FR) 1999-05-19 EP disclosed
WO-1998003490-A1 INTERMEDIATES FOR THE PREPARATION OF 2-IMIDAZOLINE-5-ONES RHONE POULENC AGRO (FR) 1998-01-29 WO disclosed
US-5470717-A Method for the preparation of certain β-lactam antibiotics GIST-BROCADES N.V. (NL) 1995-11-28 US disclosed
EP-0618979-A1 AN IMPROVED METHOD FOR THE PREPARATION OF CERTAIN $g(b)-LACTAM ANTIBIOTICS GIST-BROCADES B.V. (NL) 1994-10-12 EP disclosed
WO-1993012250-A1 AN IMPROVED METHOD FOR THE PREPARATION OF CERTAIN β-LACTAM ANTIBIOTICS NOVO NORDISK A/S (DK) 1993-06-24 WO disclosed
CN-1011784-B Process for preparing antiallergic and antimuscotromospasm agents N-benzhydryldiazacycloalkylalkyl anilides RECKORDATY CHEMICALS CORP (CH) 1991-02-27 CN disclosed
CN-86105641-A The method for preparing antianaphylaxis and antibronchospasm of N-dibenzyl-diazacyclo alkyl-alkyl-anilide 1987-04-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236107-A1 Intermediate compounds for the preparation of mirtazapine and the production methods thereof IMPDH1, MRM1, IMPDH2 MAPT 2436/4885KMT2A 2004/4885CYP1A2 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.